NCI Director and Acting FDA Commissioner Andrew von Eschenbach Endorses Rep. E. Clay Shaw In Tour of Florida Congressman’s District. Von Eschenbach Praises Shaw’s “Leadership” In Seeking Funding For Research, Support of 2015 Goal.
Shaw’s Lung Cancer, Bronchoalveolar Carcinoma, Exemplifies Elusiveness of 2015 Goal. Little Known About The Rare Disease.
Also In This 12-page Issue: NCI To Cut Budgets For New Grants By 29 Percent. R01s To Be Funded At 11th Percentile.
Trending Stories
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors









